Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS
Abstract Objectives To expand the knowledge about the immunological consequences of cladribine (CLAD), a pulsed immune reconstitution therapy approved for active multiple sclerosis (MS), beyond the known short‐term effects on peripheral immune cell subsets. Methods In this study, we characterized de...
Main Authors: | Tobias Moser, Kerstin Schwenker, Michael Seiberl, Julia Feige, Katja Akgün, Elisabeth Haschke‐Becher, Tjalf Ziemssen, Johann Sellner |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-11-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.51206 |
Similar Items
-
Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats
by: Julia Feige, et al.
Published: (2020-03-01) -
Molecular biomarkers in multiple sclerosis
by: Tjalf Ziemssen, et al.
Published: (2019-12-01) -
Response to cladribine in patient with systemic mastocytosis
by: Radojković Milica, et al.
Published: (2011-01-01) -
Should We Use Clinical Tools to Identify Disease Progression?
by: Hernan Inojosa, et al.
Published: (2021-01-01) -
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
by: Katja Akgün, et al.
Published: (2019-03-01)